Citigroup
TGTX icon

Citigroup’s TG Therapeutics TGTX Stock Holding History

Citigroup’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1M Buy
18,000
+3,000
+20% +$162K ﹤0.01% 3315
2026
Q2 		$824K Sell
15,000
-15,000
-50% -$614K ﹤0.01% 3589
2026
Q1 		$997K Buy
+30,000
New +$894K ﹤0.01% 3119
2024
Q3 		– Sell
-74,900
Closed -$1.33M – 5801
2024
Q2 		$1.33M Buy
74,900
+35,000
+88% +$558K ﹤0.01% 2683
2024
Q1 		$607K Sell
39,900
-5,000
-11% -$79.7K ﹤0.01% 3435
2023
Q4 		$767K Buy
44,900
+14,600
+48% +$170K ﹤0.01% 3067
2023
Q3 		$253K Sell
30,300
-13,500
-31% -$188K ﹤0.01% 3538
2023
Q2 		$1.09M Buy
+43,800
New +$1.13M ﹤0.01% 2785
2023
Q1 		– Sell
-59,800
Closed -$707K – 5854
2022
Q4 		$707K Buy
+59,800
New +$434K ﹤0.01% 2920
2022
Q1 		– Sell
-300,000
Closed -$5.7M – 6599
2021
Q4 		$5.7M Buy
+300,000
New +$7.79M ﹤0.01% 1730
2021
Q1 		– Sell
-18,600
Closed -$968K – 7340
2020
Q4 		$968K Hold
18,600
– – ﹤0.01% 3571
2020
Q3 		$498K Hold
18,600
– – ﹤0.01% 3847
2020
Q2 		$362K Sell
18,600
-800
-4% -$12.9K ﹤0.01% 4549
2020
Q1 		$191K Buy
19,400
+200
+1% +$2.53K ﹤0.01% 4779
2019
Q4 		$213K Sell
19,200
-6,300
-25% -$47.9K ﹤0.01% 5129
2019
Q3 		$143K Buy
25,500
+2,700
+12% +$18.8K ﹤0.01% 5419
2019
Q2 		$197K Buy
22,800
+11,300
+98% +$85.4K ﹤0.01% 5291
2019
Q1 		$92K Buy
11,500
+900
+8% +$4.86K ﹤0.01% 5828
2018
Q4 		$43K Sell
10,600
-8,700
-45% -$43.2K ﹤0.01% 6360
2018
Q3 		$108K Buy
+19,300
New +$221K ﹤0.01% 5826

Other funds holding TGTX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Citigroup's TGTX Position: Q3 2026 in Review

Citigroup reduced its TG Therapeutics (TGTX) stake by 4.8% in Q3 2026, selling an estimated $1.01M and leaving 369,396 shares worth $20.6M. The position accounts for 0.01% of the portfolio, ranked #1178.

Citigroup first reported a position in TGTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $27M in Q3 2025. 361 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

  • Citigroup held 369,396 shares of TG Therapeutics worth $20.6M as of Q3 2026.
  • Citigroup sold 18,691 TG Therapeutics shares in Q3 2026, an estimated $1.01M.
  • TG Therapeutics made up 0.01% of Citigroup's portfolio in Q3 2026, its #1178 holding.
  • Citigroup first reported a position in TG Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Citigroup's TG Therapeutics position peaked at $27M in Q3 2025.
  • 361 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.